Abstract
Recent history has witnessed unparalleled advances in our understanding of tumor biology, owing in large part to the publication of the human genome project. Paired with improvements in microarray technologies, the combination of genetic and expression profiles provides a unique opportunity to further enhance our understanding of the underlying mechanisms that drive tumor growth. Thus, integrated analysis of identified molecular changes with clinical and histologic data may further delineate a new risk stratification system for pediatric brain tumors, allowing more patient-tailored therapy and molecular-based therapeutic interventions.
Similar content being viewed by others
References and Recommended Reading
Venter JC, Adams MD, Myers EW, et al.: The sequence of the human genome. Science 2001, 291:1304–1351.
The Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008 [Epub ahead of print].
Gilbertson RJ: Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004, 5:209–218.
Avet-Loiseau H, Venuat AM, Terrier-Lacombe MJ, et al.: Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer 1999, 79:1843–1847.
Reardon DA, Michalkiewicz E, Boyett JM, et al.: Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 1997, 57:4042–4047.
Wasson JC, Saylors RL 3rd, Zeltzer P, et al.: Oncogene amplification in pediatric brain tumors. Cancer Res 1990, 50:2987–2990.
Giangaspero F, Rigobello L, Badiali M, et al.: Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol 1992, 16:687–693.
Gajjar A, Hernan R, Kocak M, et al.: Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004, 22:984–993.
Pietsch T, Waha A, Koch A, et al.: Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997, 57:2085–2088.
Hahn H, Wicking C, Zaphiropoulous PG, et al.: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841–851.
MacDonald TJ, Brown KM, LaFleur B, et al.: Expression profiling of medulloblastoma: PDGFRA and the RAS/ MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001, 29:143–152.
Gilbertson RJ, Clifford SC: PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003, 35:197–198.
Pomeroy SL, Tamayo P, Gaasenbeek M, et al.: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436–442.
Neben K, Korshunov A, Benner A, et al.: Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004, 64:3103–3111.
Mendrzyk F, Radlwimmer B, Joos S, et al.: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005, 23:8853–8862.
Lee Y, Miller HL, Jensen P, et al.: A molecular fingerprint for medulloblastoma. Cancer Res 2003, 63:5428–5437.
Kho AT, Zhao Q, Cai Z, et al.: Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev 2004, 18:629–640.
Thompson MC, Fuller C, Hogg TL, et al.: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24:1924–1931.
Gajjar A, Chintagumpala M, Ashley D, et al.: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7:813–820.
Ellison DW, Onilude OE, Lindsey JC, et al.: beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005, 23:7951–7957.
Kleihues P, Louis DN, Scheithauer BW, et al.: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002, 61:215–225; discussion 226–219.
Dyer S, Prebble E, Davison V, et al.: Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. Am J Pathol 2002, 161:2133–2141.
Hirose Y, Aldape K, Bollen A, et al.: Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 2001, 158:1137–1143.
Jeuken JW, Sprenger SH, Gilhuis J, et al.: Correlation between localization, age, and chromosomal imbalances in ependymal tumours as detected by CGH. J Pathol 2002, 197:238–244.
Grill J, Avet-Loiseau H, Lellouch-Tubiana A, et al.: Comparative genomic hybridization detects specific cytogenetic abnormalities in pediatric ependymomas and choroid plexus papillomas. Cancer Genet Cytogenet 2002, 136:121–125.
Koschny R, Koschny T, Froster UG, et al.: Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. Cancer Genet Cytogenet 2002, 135:147–159.
Ward S, Harding B, Wilkins P, et al.: Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. Genes Chromosomes Cancer 2001, 32:59–66.
Carter M, Nicholson J, Ross F, et al.: Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002, 86:929–939.
Reardon DA, Entrekin RE, Sublett J, et al.: Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer 1999, 24:230–237.
Taylor MD, Poppleton H, Fuller C, et al.: Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 2005, 8:323–335.
Ammerlaan AC, de Bustos C, Ararou A, et al.: Localization of a putative low-penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling-path genomic microarray. Genes Chromosomes Cancer 2005, 43:329–338.
Mendrzyk F, Korshunov A, Benner A, et al.: Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 2006, 12:2070–2079.
Modena P, Lualdi E, Facchinetti F, et al.: Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 2006, 24:5223–5233.
Hitoshi S, Alexson T, Tropepe V, et al.: Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev 2002, 16:846–858.
Conover JC, Doetsch F, Garcia-Verdugo JM, et al.: Disruption of Eph/ephrin signaling affects migration and proliferation in the adult subventricular zone. Nat Neurosci 2000, 3:1091–1097.
Sharma MK, Mansur DB, Reifenberger G, et al.: Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 2007, 67:890–900.
Fouladi M, Hunt DL, Pollack IF, et al.: Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children’s Cancer Group high-grade glioma study CCG-945. Cancer 2003, 98:1243–1252.
Wong KK, Tsang YT, Chang YM, et al.: Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res 2006, 66:11172–11178.
White FV, Anthony DC, Yunis EJ, et al.: Nonrandom chromosomal gains in pilocytic astrocytomas of childhood. Hum Pathol 1995, 26:979–986.
Sanoudou D, Tingby O, Ferguson-Smith MA, et al.: Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 2000, 82:1218–1222.
Pfister S, Janzarik WG, Remke M, et al.: BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008, 118:1739–1749.
Tuveson DA, Weber BL, Herlyn M: BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003, 4:95–98.
Dibb NJ, Dilworth SM, Mol CD: Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 2004, 4:718–727.
Deshmukh H, Yeh TH, Yu J, et al.: High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008, 27:4745–4751.
Faury D, Nantel A, Dunn SE, et al.: Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007, 25:1196–1208.
Khatua S, Peterson KM, Brown KM, et al.: Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Res 2003, 63:1865–1870.
Donson AM, Erwin NS, Kleinschmidt-DeMasters BK, et al.: Unique molecular characteristics of radiation-induced glioblastoma. J Neuropathol Exp Neurol 2007, 66:740–749.
Nakamura M, Shimada K, Ishida E, et al.: Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol 2007, 9:113–123.
Bredel M, Pollack IF, Hamilton RL, James CD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 1999, 5:1786–1792.
Gilbertson RJ, Hill DA, Hernan R, et al.: ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 2003, 9:3620–3624.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Johnson, R., Wright, K.D. & Gilbertson, R.J. Molecular profiling of pediatric brain tumors: Insight into biology and treatment. Curr Oncol Rep 11, 68–72 (2009). https://doi.org/10.1007/s11912-009-0011-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-009-0011-9